Chronic care sales force

Quote

anonymous

Guest
What is going to happen to us now that Steglatro truly is cooked. We were already behind the times with no CV data and now we know that we never will. Why even attempt to embarrass ourselves promoting a drug that is no better than placebo in reducing CV events when all the competition has significant data and indications showing real CV benefit. Can we survive with just Januvia? Real responses.
 






I have thought about this for sometime, given the recent remote situation we are in. The answer in the short term is YES. Long term is another question. I’m not sure when Januvia goes generic, but its at least 18 months. Therefore, Merck can keep 1 Rep per territory until either Vericiguat or Gefapixant are reviewed internally or the FDA. If either one of these medicines make it to market then I think being 1 up in Chronic Care will be the perfect number. Now if they don’t make it to market then all bets are off. I know in our Region there are lots of Reps who are multiple VP winners and Hall of Famers. I am going to guess they make between $100-120 a year. That is another situation that must be factored into Management's decisions in the future.
 






Chronic Care hall of famers and vp club winners... Might as well be a participation trophy recipient. Chronic Care blows the yeti cock - incompetent VP and DCO.

Hopefully Merck doesn’t let any of the contagion effect Oncology. Last thing we need is someone to fuck up the oncology space.
 


















Top Bottom
Back
Quote